Novartis Lescol XL
Executive Summary
Extended-release fluvastatin formulation approved by FDA Oct. 6 in an 80 mg dose. Both regular and extended-release Lescol formulations add a new indication for use as a secondary supplement to diet "to increase high-density lipoprotein cholesterol in patients with primary hyper-cholesterolemia and mixed dyslipidemia"